MindMed announces the appointment of Andreas Krebs and Carol Vallone as directors and the transition of Bruce Linton
NEW YORK, September 30, 2021 / PRNewswire / – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (“MindMed” or the “Company”), a leading biotechnology company that develops therapies for psychedelic inspiration, is delighted to announce that its board of directors has appointed Mr. Andreas Krebs and Mrs. Carole Valloné as directors of the Company, with immediate effect.
Mr. Krebs is an internationally experienced executive, entrepreneur and bestselling author (“The Illusion of Invincibility”). He heads the family-owned investment company Longfield Invest (Langenfeld /Germany), which focuses on growing companies in various industries as well as the new economy. He worked in seven countries, in Latin America, Asia and Canada and as chairman and member of the board of directors of Wyeth Corporation in United States. Andreas Krebs was Chairman of the Supervisory Board and the Board of Shareholders of Merz Pharma, Frankfurt am the main one, Germany from 2010 to 2019, is currently a member of the supervisory board of the European group of eye clinics Veonet (Nordic Capital Group) and holds other positions on the board of directors in various sectors. In addition, he is president of the private non-governmental organization Förderverein Girassol eV, which supports children and young people from socially difficult backgrounds in São Paulo, Brazil.
Ms. Vallone is a well-known business leader, former CEO and board director, with extensive experience in launching, scaling and selling global businesses. Currently, she is Chair of the Board of Directors of McLean Hospital, the No.1 ranked independent psychiatric hospital and largest psychiatric affiliate in Harvard Medical School; sits on the board of directors of the MGH’s Institute of Health Professions; and sits on Mass General Brigham’s finance committee. In addition, Ms. Vallone is a member of the board of directors of Cresco Labs, a publicly traded company, and of a portfolio company of Bain Capital Double Impact, Arosa. She is also an advisory director for investment firm Berkshire Partners and a member of the advisory board of healthcare-focused venture capital growth firm, Longitude Capital. A serial entrepreneur, Ms. Vallone has been the founder and CEO of global e-learning companies, held leadership roles in leading technology companies, and served on the boards of public financial services and corporate organizations. e-commerce.
Mr. Krebs said: “Mental health issues have a direct or indirect impact on almost every one of us at some point in our lives. I am delighted to have the opportunity to help MindMed find better solutions to this huge challenge in the years to come. ”
Ms. Vallone said: “I feel privileged to support the esteemed team of scientists and professionals at MindMed in the search for new drugs and therapies for those suffering from mental illness.
Effective September 29, 2021, Sir. Bruce linton resigned from the Board of Directors of the Company in order to make way for the appointment of Ms. Vallone and Mr. Krebs. Mr Linton said: “In just over two years, MindMed has grown from a topic that frankly was difficult to find support for, to attracting world-class talent and significant capacity capital. He added: “I am delighted with the accession of applicants and look forward to the world of change MindMed can achieve.
MindMed chair Perry dellelce said: “We are extremely pleased to welcome Carol and Andreas to the Board of Directors. The depth of their collective experience with pharmaceutical, technology and health-focused organizations, combined with their extensive service on the boards of public companies, will broaden and deepen the capabilities of the board of directors of the company. Further, on behalf of the Board of Directors, I would like to thank Bruce for his support and dedicated service to the Board of the Company since the inception of the Company. I look forward to working with him on his next endeavors. ”
The appointment of Mr. Krebs and Ms. Vallone is subject to regulatory approval.
MindMed is a clinical-stage psychedelic medicine biotechnology company that seeks to discover, develop and deploy psychedelically inspired drugs and therapies to combat addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative therapies based on psychedelics, including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed leadership team brings extensive biopharmaceutical experience to MindMed’s approach to develop the next generation of psychedelically inspired drugs and therapies.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also marketed Germany under the acronym MMQ.
Certain statements in this press release concerning the Company constitute “forward-looking information” within the meaning of applicable securities laws and are forward-looking in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections regarding future events and is therefore subject to risks and uncertainties that could cause actual results to differ materially from future results. expressed or implied by forward-looking statements. . These statements can generally be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate” , “,” believe “,” potential “or” continue “, or the negative thereof or similar variations. Forward-looking information contained in this press release includes, without limitation, statements regarding the appointment of Mr. Krebs and Ms. Vallone to the Board of Directors of the Company, regulatory approval and anticipated future business plans and operations. Although the Company believes that the expectations reflected in this forward-looking information are reasonable, such information implies risks and uncertainties, and you should not place undue reliance on this information, as unknown or unforeseeable factors could have material adverse effects on the future results, performance or achievements of the Company. é. There are numerous risks and uncertainties which could cause the actual results and the plans and objectives of the Company to differ materially from those expressed in the forward-looking information, including compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; increased regulatory control; early stage product development; risks associated with clinical trials; regulatory approval process; the novelty of the psychedelic-inspired drug industry; as well as the risk factors discussed or mentioned herein and the risks described under the headings “Risk Factors” in the documents filed by the Company with the securities regulators of all the provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and from the United States Securities and Exchange Commission on EDGAR at www.sec.gov. If one or more of these risks or uncertainties materialize, or if the assumptions underlying the forward-looking information prove to be incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify risks, uncertainties and important factors that could cause actual results to differ materially, there may be others that could cause results not to be as anticipated. , estimated or planned. This subsequent written and oral forward-looking information and all subsequent forward-looking information are based on management’s estimates and opinions on the dates on which they are made and are expressly qualified in their entirety by this notice. Unless required by law, the Company does not intend and assumes no obligation to update this forward-looking information.
Media contact: [email protected]
SOURCE Mind Medicine (MindMed) Inc.